Dettmar P W, Little S L, Baxter T
Reckitt Benckiser Healthcare (UK) Ltd, Hull, UK.
J Int Med Res. 2005 May-Jun;33(3):301-8. doi: 10.1177/147323000503300305.
Alginate-based reflux suppressant preparations provide symptom relief by forming a physical barrier on top of the stomach contents in the form of a neutral floating gel or raft. This study investigated whether reduced acidity in the stomach brought about by omeprazole pre-treatment affected the formation and gastric residence time of alginate rafts. It was a balanced, cross-over study in 12 healthy non-patient volunteers following a single dose of two indium-111-labelled alginate tablets in the presence or absence of 3 days' pre-treatment with omeprazole. Raft formation and gastric residence, in the presence of a technetium-99m-labelled meal, were assessed by gamma scintigraphy for 3 h after alginate tablet administration. The relative raft-forming ability of alginate tablets after omeprazole compared with alginate tablets alone was 0.950 with 95% confidence intervals of 0.882 and 1.018. Pre-treatment and co-administration with omeprazole has no significant effect on the raft-forming ability of alginate tablets.
基于海藻酸盐的抗反流制剂通过在胃内容物上方形成中性漂浮凝胶或筏状的物理屏障来缓解症状。本研究调查了奥美拉唑预处理导致的胃内酸度降低是否会影响海藻酸盐筏的形成和胃内停留时间。这是一项针对12名健康非患者志愿者的平衡交叉研究，在有或没有奥美拉唑3天预处理的情况下，单次服用两片铟-111标记的海藻酸盐片剂。在服用海藻酸盐片剂后3小时，通过γ闪烁扫描法评估在有锝-99m标记餐的情况下筏的形成和胃内停留情况。与单独的海藻酸盐片剂相比，奥美拉唑处理后的海藻酸盐片剂的相对筏形成能力为0.950，95%置信区间为0.882和1.018。奥美拉唑预处理和联合给药对海藻酸盐片剂的筏形成能力没有显著影响。
